By Frank Prenesti
Date: Tuesday 18 May 2021
LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.
Oxford Biomedica, which has an 18-month supply deal with AstraZeneca to make its AZD1222 vaccine, lifted forecasts for expected cumulative revenues to more than £100m by end-2021 from more than £50m.
As a result, Oxford Biomedica said it expected 'significant growth' in annual operating earnings for the year to end-December.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 218.50p |
Change Today | 3.50p |
% Change | 1.63 % |
52 Week High | 470.00 |
52 Week Low | 166.80 |
Volume | 249,723 |
Shares Issued | 100.00m |
Market Cap | £218.50m |
RiskGrade | 125 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 3 |
Neutral | 6 |
Sell | 0 |
Strong Sell | 0 |
Total | 10 |
No dividends found |
Time | Volume / Share Price |
17:59 | 26,338 @ 219.50p |
17:07 | 2,500 @ 218.50p |
16:35 | 13,698 @ 218.50p |
16:35 | 240 @ 218.50p |
16:35 | 919 @ 218.50p |
You are here: research